Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Inovio Pharmaceuticals stock | $17

Own Inovio Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Inovio Pharmaceuticals, Inc is a biotechnology business based in the US. Inovio Pharmaceuticals shares (INO) are listed on the NASDAQ and all prices are listed in US Dollars. Inovio Pharmaceuticals employs 190 staff and has a trailing 12-month revenue of around USD$2.7 million.

How to buy shares in Inovio Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Inovio Pharmaceuticals Find the stock by name or ticker symbol: INO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Inovio Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$17, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Inovio Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Inovio Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Inovio Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Inovio Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$17, which is 77.97% up on its pre-crash value of USD$3.745 and 441.40% up on the lowest point reached during the March crash when the shares fell as low as USD$3.14.

If you had bought USD$1,000 worth of Inovio Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$1,693.07 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$4,347.75.

Inovio Pharmaceuticals share price

Use our graph to track the performance of INO stocks over time.

Inovio Pharmaceuticals shares at a glance

Information last updated 2020-09-20.
Latest market closeUSD$17
52-week rangeUSD$1.96 - USD$33.79
50-day moving average USD$14.2144
200-day moving average USD$14.3568
Wall St. target priceUSD$19
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.215

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Vanguard
Stocks,Mutual funds,ETFs,Forex
$0
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
Stocks,Options,ETFs,Cryptocurrency
$0
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
Stocks,Options,ETFs,Futures
$0
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
M1 Finance
M1 Finance
Stocks,ETFs
$0
$0
0%
A robo-advisor that puts you in the driver’s seat with fully-customizable portfolios.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Inovio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inovio Pharmaceuticals price performance over time

Historical closes compared with the last close of $17

1 week (2020-09-14) 50.18%
1 month (2020-08-21) 20.57%
3 months (2020-06-19) 19.13%
6 months (2020-03-20) 135.46%
1 year (2019-09-20) 585.48%
2 years (2018-09-21) 259.41%
3 years (2017-09-21) 170.27%
5 years (2015-09-21) 133.20%

Inovio Pharmaceuticals financials

Revenue TTM USD$2.7 million
Gross profit TTM USD$-82,005,389
Return on assets TTM -22.79%
Return on equity TTM -184.48%
Profit margin 0%
Book value $1.173
Market capitalisation USD$2.8 billion

TTM: trailing 12 months

Shorting Inovio Pharmaceuticals shares

There are currently 30.9 million Inovio Pharmaceuticals shares held short by investors – that's known as Inovio Pharmaceuticals's "short interest". This figure is 20% up from 25.8 million last month.

There are a few different ways that this level of interest in shorting Inovio Pharmaceuticals shares can be evaluated.

Inovio Pharmaceuticals's "short interest ratio" (SIR)

Inovio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Inovio Pharmaceuticals shares currently shorted divided by the average quantity of Inovio Pharmaceuticals shares traded daily (recently around 9.4 million). Inovio Pharmaceuticals's SIR currently stands at 3.3. In other words for every 100,000 Inovio Pharmaceuticals shares traded daily on the market, roughly 3300 shares are currently held short.

However Inovio Pharmaceuticals's short interest can also be evaluated against the total number of Inovio Pharmaceuticals shares, or, against the total number of tradable Inovio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inovio Pharmaceuticals's short interest could be expressed as 0.31% of the outstanding shares (for every 100,000 Inovio Pharmaceuticals shares in existence, roughly 310 shares are currently held short) or 0.3158% of the tradable shares (for every 100,000 tradable Inovio Pharmaceuticals shares, roughly 316 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inovio Pharmaceuticals.

Find out more about how you can short Inovio Pharmaceuticals stock.

Inovio Pharmaceuticals share dividends

We're not expecting Inovio Pharmaceuticals to pay a dividend over the next 12 months.

Have Inovio Pharmaceuticals's shares ever split?

Inovio Pharmaceuticals's shares were split on a 1:4 basis on 6 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Inovio Pharmaceuticals shares which in turn could have impacted Inovio Pharmaceuticals's share price.

Inovio Pharmaceuticals share price volatility

Over the last 12 months, Inovio Pharmaceuticals's shares have ranged in value from as little as $1.96 up to $33.79. A popular way to gauge a stock's volatility is its "beta".

INO.US volatility(beta: 1.09)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 1.0903. This would suggest that Inovio Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Inovio Pharmaceuticals overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site